This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

# **Revision of PRECAUTIONS**

## **Edoxaban tosilate hydrate**

November 26, 2025

Therapeutic category

Anticoagulants

### Non-proprietary name

Edoxaban tosilate hydrate

### Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

#### Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS	11. ADVERSE REACTIONS
11.1. Clinically Significant Adverse Reactions	11.1. Clinically Significant Adverse Reactions
Haemorrhage	Haemorrhage
Significant haemorrhage affecting various tissues and organs may	Significant haemorrhage affecting various tissues and organs may
occur, including haemorrhage of digestive tract, haemorrhage	occur, including haemorrhage of digestive tract, haemorrhage
intracranial, haemorrhage intraocular, wound haemorrhage, and	intracranial, haemorrhage intraocular, wound haemorrhage,
retroperitoneal haemorrhage. Some fatal cases have also been	retroperitoneal haemorrhage, and splenic haemorrhage leading to
reported. If clinically significant haemorrhage occurs or worsens,	splenic rupture. Some fatal cases have also been reported. If
administration should be discontinued.	clinically significant haemorrhage occurs or worsens, administration
	should be discontinued.